Table 3C.
Prevalence of HR-HPV genotypes in HR-HPV-positive cervical lesions in the total study population
| HR-HPV genotypes |
<CIN2 (n=513) | HR-HPV genotypes |
CIN2 (n=93) | HR-HPV genotypes |
CIN3+ (n=39) | HR-HPV genotypes |
Total (n=645) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No | % | No | % | No | % | No | % | ||||
| HPV16 | 174 | 33.92 | HPV16 | 49 | 52.69 | HPV16 | 32 | 82.05 | HPV16 | 255 | 39.53 |
| HPV58 | 94 | 18.32 | HPV58 | 16 | 17.20 | HPV58 | 5 | 12.82 | HPV58 | 115 | 17.83 |
| HPV52 | 89 | 17.35 | HPV31 | 12 | 12.90 | HPV33 | 4 | 10.26 | HPV52 | 100 | 15.50 |
| HPV53 | 43 | 8.38 | HPV33 | 12 | 12.90 | HPV31 | 4 | 10.26 | HPV53 | 47 | 7.29 |
| HPV51 | 39 | 7.60 | HPV52 | 11 | 11.83 | HPV18 | 2 | 5.13 | HPV51 | 47 | 7.29 |
| HPV66 | 30 | 5.85 | HPV51 | 8 | 8.60 | HPV66 | 2 | 5.13 | HPV33 | 46 | 7.13 |
| HPV68 | 30 | 5.85 | HPV18 | 6 | 6.45 | HPV53 | 2 | 5.13 | HPV31 | 38 | 5.89 |
| HPV33 | 29 | 5.65 | HPV56 | 5 | 5.38 | HPV56 | 1 | 2.56 | HPV66 | 34 | 5.27 |
| HPV39 | 28 | 5.46 | HPV66 | 3 | 3.23 | HPV35 | 1 | 2.56 | HPV56 | 33 | 5.12 |
| HPV56 | 27 | 5.26 | HPV39 | 2 | 2.15 | HPV59 | 1 | 2.56 | HPV68 | 31 | 4.81 |
| HPV31 | 22 | 4.29 | HPV53 | 2 | 2.15 | HPV52 | 0 | 0.00 | HPV39 | 30 | 4.65 |
| HPV18 | 20 | 3.90 | HPV68 | 1 | 1.08 | HPV51 | 0 | 0.00 | HPV18 | 28 | 4.34 |
| HPV59 | 17 | 3.31 | HPV35 | 1 | 1.08 | HPV68 | 0 | 0.00 | HPV59 | 18 | 2.79 |
| HPV35 | 11 | 2.14 | HPV59 | 0 | 0.00 | HPV39 | 0 | 0.00 | HPV35 | 13 | 2.02 |
| HPV45 | 3 | 0.58 | HPV45 | 0 | 0.00 | HPV45 | 0 | 0.00 | HPV45 | 3 | 0.47 |
Abbreviations: ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HR-HPV, high-risk human papillomavirus.